BIIB 110
Alternative Names: ALG 801; BIIB-110Latest Information Update: 09 Jan 2025
At a glance
- Originator AliveGen
- Developer AliveGen; Biogen
- Class Recombinant proteins
- Mechanism of Action Type II-B activin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
- No development reported Spinal muscular atrophy
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 18 Nov 2024 BIIB 110 receives Orphan Drug status for Pulmonary arterial hypertension in USA
- 28 Sep 2024 No recent reports of development identified for phase-I development in Spinal-muscular-atrophy(In volunteers) in USA
- 18 Mar 2024 Pharmacodynamics, pharmacokinetics and adverse events data from a phase I trial in Spinal muscular atrophy released by AliveGen